dysautonomia, and studied the 2 groups across different timepoints: Day 120, Day 305 and Day 731. When we analyzed the data a few interesting things popped out at us. First, IMC-2 + Paxlovid outperforms IMC-2 alone in improving fatigue, dysautonomia and brain fog (p<0.0001).
11/